CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$47.85 USD
-1.00 (-2.05%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $47.98 +0.13 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.85 USD
-1.00 (-2.05%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $47.98 +0.13 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
by Zacks Equity Research
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.
Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 105.26%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Panbela (PBLA) Regains Flynpovi Rights to Treat FAP
by Zacks Equity Research
Panbela (PBLA) shares surge as it regains rights to develop and commercialize Flynpovi for the familial adenomatous polyposis treatment.
Apellis (APLS) Stock Up 50% in Three Months: Here's Why?
by Zacks Equity Research
Apellis (APLS) stock rises 50% in the past three months owing to the approval of Syfovre (pegcetacoplan injection) in February. An encouraging uptake in its first marketed product, Empaveli, also contributed to the surge.
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
by Zacks Equity Research
The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
by Zacks Equity Research
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
by Zacks Equity Research
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
by Zacks Equity Research
As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio
by Zacks Equity Research
Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
by Zacks Equity Research
VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel
by Zacks Equity Research
CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
by Zacks Equity Research
Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.
Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies
by Zacks Equity Research
The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.
CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $45.28, moving +0.11% from the previous trading session.
Emergent Biosciences (EBS) Surges 28% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose
by Zacks Equity Research
Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of this year.
Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study
by Zacks Equity Research
Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.
Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
by Zacks Equity Research
Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe
by Zacks Equity Research
Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan
by Zacks Equity Research
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio
by Zacks Equity Research
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.